With two new vice presidents and three new board members, PHARMIG is heading into the next 70 years
Vienna (OTS) – PHARMIG, the association of the Austrian pharmaceutical industry, held its 70th general meeting today and celebrated its 70th anniversary, including in the presence of Federal Minister Johannes Rauch. Elisabeth Keil (Daiichi Sankyo Austria GmbH) and Nicole Daniela Schlautmann (Pfizer Corporation Austria Gesellschaft mbH) were confirmed as new vice-presidents at the general meeting. Together with President Ingo Raimon (AbbVie GmbH) and Vice President Bernhard Wittmann (Sigmapharm Arzneimittel GmbH), they form the executive committee in Austria’s voluntary representation of interests for the entire pharmaceutical industry.
There are also the following new additions to the PHARMIG board: Kuntal Baveja (Novartis Pharma GmbH), Julia Guizani (sanofi-aventis GmbH, Austria) and Peter Stenico (Sandoz GmbH) were already co-opted board members and were confirmed as full board members by the general meeting . The former president and vice president Philipp von Lattorff was appointed honorary board member.
Following the general meeting, PHARMIG celebrated its 70th anniversary. PHARMIG President Ingo Raimon emphasized the importance of a strong association in view of the numerous challenges for Austria as a business and pharmaceutical location: “Our association has given the pharmaceutical industry a powerful voice for 70 years. He has been committed to ensuring the best possible supply of medication in Austria for 70 years. Our focus is also on a location where the companies in our industry can make their contribution to good and safe jobs, to strengthening the infrastructure in their immediate surroundings and also to overall value creation. The basis for this is strong solidarity, in keeping with the motto of our celebration, ‘Connection works’. In a highly dynamic environment, we can only advance sustainable solutions together and create a strong, future-proof Austrian pharmaceutical location. I would therefore like to thank all member companies for making this solidarity possible.”
For Raimon, the topics of drug supply and drug diversity stand out from the association’s diverse range of activities: “The best possible therapy can only be used if it is available to patients. The recent past has shown that reimbursement and location policies must complement each other and not contradict each other. Anyone who invests in pharmaceuticals is therefore investing in Austria as a location, in its competitiveness and, probably most importantly, in the quality of care.”
PHARMIG General Secretary Alexander Herzog emphasized on the occasion of the event: “We have been helping shape things for 70 years. In the course of this, we consolidate positions from the entire industry, mediate between the often different interests of our members and thus lead a continuous, appreciative dialogue with all of our partners in the healthcare sector with a strong voice. We can do this because all those who work in and for the association put what connects before what separates, in the sense of ‘connectedness works’. The association has a wide range of experience and expertise so that it can continue to provide important impetus for a strong research and pharmaceutical location in the future.”
Finally, Herzog emphasized in particular the necessity and benefit of long-term perspectives in order to continue to set positive and sustainable accents to strengthen Austria and Europe.
The Executive Board of PHARMIG (term of office until 2025):
President Mag. Ingo Raimon (AbbVie GmbH)
Vice President Mag. (FH) Elisabeth Keil (DAIICHI SANKYO AUSTRIA GmbH)
Vice President Dipl. rer. nat. Nicole Schlautmann, MBA (Pfizer Corporation Austria Gesellschaft mbH)
Vice President Dr. Bernhard Wittmann (Sigmapharm Arzneimittel GmbH)
The board members of PHARMIG (term of office until 2025):
Kuntal Baveja (Novartis Pharma GmbH)
Dipl.-Math. Susanne Erkens-Reck (Roche Austria GmbH)
Dipl.-Kfr. Julia Guizani, MBA (sanofi-aventis GmbH, Austria)
Lieven Hentschel (Bayer Austria Gesellschaft mbH)
Ina Herzer (Merck Sharp & Dohme Ges.m.b.H.)
Ing. Mag. Roland Huemer (Richter Pharma AG)
KommR. Dkfm. Dr. Johann F. Kwizda (Kwizda Pharma GmbH)
dr. Beate Pettinger-Natmeßnig (CSL Behring GmbH)
Mag. Elgar Schnegg, MBA (Ratiopharm Arzneimittel Vertriebs-GmbH)
Peter Stenico (Sandoz GmbH)
Mag. Wolfgang Wacek (Sanova Pharma GmbH)
Information can also be found at https://www.pharmig.at/der-verband/über-uns/
About PHARMIG: PHARMIG is the voluntary interest group of the Austrian pharmaceutical industry. The association currently has around 120 members (as of May 2024), who cover a good 95 percent of the medication market. PHARMIG and its member companies stand for the best possible security of supply of medicines in the healthcare system and ensure social and medical progress through quality and innovation.
Questions & Contact:
PHARMIG – Association of the Austrian Pharmaceutical Industry
Peter Richter, BA MA MBA
Head of Communications & PR
+43 664 8860 5264
peter.richter@pharmig.at
www.pharmig.at